LIXTE issues registered pre-funded warrants to purchase common stock

LIXTE Biotechnology Holdings issued pre-funded warrants with an initial exercise date in June 2026 as part of a securities purchase agreement. The warrant issuance expands the company's capital structure and provides investors with equity upside potential.